30-day average of 13 articles · scale −100 to +100
Across 13 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Cigna news is Somewhat Bullish (+35)
on a scale from −100 to +100.
That is down 7 points from the previous 30 days (+42).
🏢 CI operates via Cigna Healthcare and Evernorth Health Services segments.
⚠️ CI faces 2027 headwinds like declining pharmacy membership and ACA exit.
Somewhat Bullish +45
Is Wall Street Bullish or Bearish on Cigna Group Stock?
AI-generated analysis
Key insights
🏢 Cigna Group operates through two main segments: Cigna Healthcare providing medical and insurance solutions, and Evernorth Health Services focusing on pharmacy benefits and drug distribution.
📉 Stock performance has underperformed benchmarks, with shares up 9.5% over the past 52 weeks versus the S&P 500's 10.8% gain and trailing the IHF Healthcare ETF by 14 percentage points.
⚠️ Management identified specific 2027 headwinds including declining pharmacy membership, weaker pharmacy benefit earnings, ACA market exit, and a slower specialty drug pipeline.
📈 The company has maintained a track record of beating consensus EPS estimates in each of the past four quarters despite mixed stock price action.
👥 Analyst consensus is a 'Moderate Buy' with 14 'Strong Buy' ratings out of 23 covers, indicating overall bullish sentiment from Wall Street.
💰 Wells Fargo raised its price target to $325 while maintaining an 'Equal Weight' rating, reflecting a nuanced view on the stock's prospects.
🎯 The mean analyst price target of $347.17 implies 17.2% upside potential relative to the current share price as of publication.
📅 Cigna has successfully upgraded its full-year outlook, providing support for the stock despite recent volatility following Q3 earnings.
📈 Bullish signals
📈Cigna has surpassed consensus EPS estimates in each of the past four quarters, demonstrating a steady track record of delivering stronger-than-expected results.
📅The company recently upgraded its full-year outlook, providing fundamental support for the stock despite recent price volatility.
👥Analyst consensus is a 'Moderate Buy' with 14 out of 23 ratings classified as 'Strong Buy', indicating strong institutional confidence.
📉 Risk factors
📅Shares slipped following Q3 results on November 5, even though the company beat revenue and earnings estimates, signaling investor concern about future guidance.
⚠️Management explicitly flagged declining pharmacy membership and weaker pharmacy benefit earnings as significant challenges for 2027.
Article
Cigna Group (CI), a global healthcare company with a market cap of approximately $79.4 billion, operates through Cigna Healthcare and Evernorth Health Services. The business serves over 185 million customer relationships across more than 30 markets, offering medical, dental, behavioral health, and insurance solutions alongside pharmacy benefits and drug distribution services.
Despite strong operational fundamentals including repeated Wall Street beats and an upgraded full-year outlook, Cigna's stock performance has lagged the broader market. Shares have risen 9.5% over the past 52 weeks compared to the S&P 500's 10.8% gain, and the company trails its healthcare peers significantly in 2026 year-to-date returns.
Following Q3 results on November 5, where shares slipped despite beating revenue and earnings estimates, investors are concerned about headwinds facing the company in 2027. Management has specifically flagged declining pharmacy membership, weaker pharmacy benefit earnings, an exit from the ACA market, and a slower specialty drug pipeline as key challenges ahead.
Analyst sentiment remains cautiously positive with a consensus 'Moderate Buy' rating based on 23 covers. Wells Fargo recently raised its price target to $325, while the average analyst price target of $347.17 implies a 17.2% premium to current levels, suggesting potential upside despite near-term operational concerns.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Cigna Group (CI), a global healthcare company with a market cap of approximately $79.4 billion, operates through Cigna Healthcare and Evernorth Health Services. The business serves over 185 million customer relationships across more than 30 markets, offering medical, dental, behavioral health, and insurance solutions alongside pharmacy benefits and drug distribution services.
Despite strong operational fundamentals including repeated Wall Street beats and an upgraded full-year outlook, Cigna's stock performance has lagged the broader market. Shares have risen 9.5% over the past 52 weeks compared to the S&P 500's 10.8% gain, and the company trails its healthcare peers significantly in 2026 year-to-date returns.
Following Q3 results on November 5, where shares slipped despite beating revenue and earnings estimates, investors are concerned about headwinds facing the company in 2027. Management has specifically flagged declining pharmacy membership, weaker pharmacy benefit earnings, an exit from the ACA market, and a slower specialty drug pipeline as key challenges ahead.
Analyst sentiment remains cautiously positive with a consensus 'Moderate Buy' rating based on 23 covers. Wells Fargo recently raised its price target to $325, while the average analyst price target of $347.17 implies a 17.2% premium to current levels, suggesting potential upside despite near-term operational concerns.
🏢 CI operates via Cigna Healthcare and Evernorth Health Services segments.
📉 CI shares rose 9.5% in 52 weeks, trailing S&P 500 gains.
⚠️ CI faces 2027 headwinds like declining pharmacy membership and ACA exit.
📈 CI beat EPS estimates for four consecutive quarters despite stock lag.
🎯 Analysts imply 17.2% upside with a mean price target of $347.
🏢 Cigna Group operates through two main segments: Cigna Healthcare providing medical and insurance solutions, and Evernorth Health Services focusing on pharmacy benefits and drug distribution.
📉 Stock performance has underperformed benchmarks, with shares up 9.5% over the past 52 weeks versus the S&P 500's 10.8% gain and trailing the IHF Healthcare ETF by 14 percentage points.
⚠️ Management identified specific 2027 headwinds including declining pharmacy membership, weaker pharmacy benefit earnings, ACA market exit, and a slower specialty drug pipeline.
📈 The company has maintained a track record of beating consensus EPS estimates in each of the past four quarters despite mixed stock price action.
👥 Analyst consensus is a 'Moderate Buy' with 14 'Strong Buy' ratings out of 23 covers, indicating overall bullish sentiment from Wall Street.
💰 Wells Fargo raised its price target to $325 while maintaining an 'Equal Weight' rating, reflecting a nuanced view on the stock's prospects.
🎯 The mean analyst price target of $347.17 implies 17.2% upside potential relative to the current share price as of publication.
📅 Cigna has successfully upgraded its full-year outlook, providing support for the stock despite recent volatility following Q3 earnings.
Bullish Signals
Surpassed EPS estimates for four consecutive quarters.
Upgraded full-year outlook supports stock despite volatility.
Analyst consensus is Moderate Buy with 14 Strong Buys.
Risk Factors
Shares slipped despite beating estimates due to weak guidance.
Management warned of declining pharmacy membership and earnings.
Bullish Signals
Cigna has surpassed consensus EPS estimates in each of the past four quarters, demonstrating a steady track record of delivering stronger-than-expected results.
The company recently upgraded its full-year outlook, providing fundamental support for the stock despite recent price volatility.
Analyst consensus is a 'Moderate Buy' with 14 out of 23 ratings classified as 'Strong Buy', indicating strong institutional confidence.
Risk Factors
Shares slipped following Q3 results on November 5, even though the company beat revenue and earnings estimates, signaling investor concern about future guidance.
Management explicitly flagged declining pharmacy membership and weaker pharmacy benefit earnings as significant challenges for 2027.
The Cigna Group reported a stronger third-quarter performance, with revenue rising 6 percent year over year to $73.7 billion for the three months ended September 30. Adjusted earnings from operations reached $2.1 billion, or $7.98 per share, driven by improved efficiency and higher net investment income within its Healthcare segment.
Management has lifted its minimum full-year adjusted EPS outlook for 2026 to $30.60, an increase of $0.15 from the prior projection. This revised guidance includes anticipated dividends and future share repurchases, signaling confidence in the company's ability to meet its financial targets despite a decline in reported net income due to the absence of a prior-year gain on sale.
Cigna Healthcare was the primary driver of earnings improvement, with adjusted revenue up 9 percent to $11.7 billion and pretax adjusted income increasing 15 percent to $1.2 billion. The segment's medical care ratio improved slightly to 85.0 percent, while management narrowed its full-year expected range and raised the pretax adjusted earnings floor by $50 million.
Evernorth Health Services generated adjusted revenue of $63.8 billion, up 6 percent from the prior year. While Specialty and Care Services earnings increased 15 percent, Pharmacy Benefit Services earnings declined amid client contract renewals and strategic investments. The company also repurchased 1.8 million shares for approximately $500 million through November 4.
📈 Cigna Group Q3 revenue rose 6% to $73.7 billion.
💰 Adjusted EPS reached $7.98, lifting 2026 outlook to $30.60.
🏥 Healthcare revenue grew 9% with pretax income up 15%.
📉 Reported net income dropped due to lack of prior-year gain.
🔧 CEO Evanko highlighted progress on Accelerate to One initiative.
📈 Cigna Group revenue rose 6% year over year to $73.7 billion in the third quarter ended September 30.
💰 Adjusted earnings from operations reached $2.1 billion, or $7.98 per share, compared to $7.83 a year earlier.
🚀 Management lifted the minimum 2026 adjusted EPS outlook to $30.60, an increase of $0.15 from the prior projection.
🏥 Cigna Healthcare adjusted revenue increased 9% to $11.7 billion with pretax adjusted income up 15% to $1.2 billion.
📉 Reported net income declined to $1.4 billion due to the absence of a prior-year gain on sale, not operational weakness.
💊 Evernorth Health Services revenue grew 6% to $63.8 billion, with Specialty and Care Services earnings up 15%.
📉 Pharmacy Benefit Services earnings declined amid client contract renewals and strategic investments within the Evernorth segment.
🏦 The company repurchased 1.8 million shares for approximately $500 million through November 4.
🎯 Management narrowed the full-year medical care ratio expectation to 84.2% plus or minus 25 basis points.
🔧 CEO Brian Evanko highlighted progress on the Accelerate to One modernization and productivity initiative.
Bullish Signals
EPS outlook raised to $30.60 for 2026.
Q3 revenue grew 6% YoY to $73.7B.
Healthcare pretax income rose 15% to $1.2B.
Repurchased 1.8M shares for ~$500M.
Medical care ratio expectation narrowed to 84.2%.
Risk Factors
Net income dropped $1.4B vs $1.9B due to missing gain.
Evernorth PBM earnings fell amid renewals and investments.
Bullish Signals
Cigna Group lifted its minimum 2026 adjusted EPS outlook to $30.60, an increase of $0.15 from the prior projection.
Third-quarter revenue rose 6% year over year to $73.7 billion, demonstrating solid top-line growth.
Cigna Healthcare delivered a 9% increase in adjusted revenue and a 15% rise in pretax adjusted income to $1.2 billion.
The company repurchased 1.8 million shares for approximately $500 million through November 4, supporting share price.
Management narrowed the full-year medical care ratio expectation to 84.2% plus or minus 25 basis points, indicating improved efficiency.
Evernorth's Specialty and Care Services earnings increased 15% to $1.1 billion, contributing to overall segment strength.
Risk Factors
Reported net income declined to $1.4 billion from $1.9 billion primarily due to the absence of an after-tax gain on a sale that benefited the third quarter of 2025.
Evernorth's Pharmacy Benefit Services earnings declined amid client contract renewals and strategic investments within the segment.
Cigna Group (CI) shares recently closed at US$301.48, reflecting a cumulative 52.0% gain over the past five years. The article evaluates whether this valuation is justified by current earnings power, noting that recent reports of higher earnings and an upgraded full-year outlook suggest investors are pricing in stronger profitability and cash generation capabilities.
On a price-to-earnings basis, CI trades at approximately 12.4x earnings, significantly lower than the wider Healthcare sector average of roughly 24.9x and peer group averages around 27.0x. This substantial discount suggests the market is assigning a lower multiple to Cigna compared to comparable businesses, while a fair value framework weighing growth, profitability, and risk indicates the current multiple screens as undervalued.
Management has recently lifted its 2026 earnings outlook, creating a contrast between upgraded profit expectations and the currently discounted P/E ratio. Community analysis from Simply Wall St identifies one of the top narratives suggesting CI is 11% undervalued, contingent on the company successfully transitioning clients to its Signature rebate-free PBM model while maintaining specialty earnings and customer retention.
The article concludes that while current multiples tell only part of the story, professional analyst views provide detailed perspectives on Cigna's trajectory. The analysis relies on historical data and unbiased methodology without constituting a specific recommendation to buy or sell, aiming instead to offer long-term fundamental analysis driven by financial metrics.
📈 CI shares gained 52.0% total return over the past five years.
💰 Stock closed at US$301.48 with a P/E ratio of 12.4x.
📉 Valuation is significantly lower than Healthcare sector and peer averages.
🚀 Management raised full-year earnings outlook and 2026 forecast.
🎯 CI could be 11% undervalued if Signature PBM transition succeeds.
📈 Cigna Group (CI) shares have climbed steadily over the past five years, achieving a total return of 52.0%.
💰 The stock recently closed at US$301.48, prompting an evaluation of whether current earnings justify this price level.
📉 CI trades at a P/E ratio of approximately 12.4x, which is significantly lower than the Healthcare sector average of 24.9x and peer group averages of 27.0x.
🚀 Management has recently lifted its full-year earnings outlook and specifically raised the 2026 earnings forecast.
📊 A fair value framework analysis suggests CI is currently undervalued relative to its growth profile, profitability, size, and risk factors.
🎯 Community narratives indicate CI could be 11% undervalued if the company successfully transitions clients to the Signature rebate-free PBM model.
🛡️ The valuation thesis relies on Cigna maintaining specialty earnings, managing medical cost trends, and ensuring strong customer retention.
📝 Simply Wall St analysts provide detailed views on where CI could be positioned a few years from now based on fundamental data.
Bullish Signals
Shares delivered 52.0% total return over past five years.
Bullish Signals
Cigna Group shares have delivered a substantial 52.0% total return over the past five years, demonstrating strong long-term performance.
The company recently reported higher earnings and upgraded its full-year outlook, signaling improved profitability and cash generation prospects.
CI trades at a P/E ratio of approximately 12.4x, which is significantly lower than the wider Healthcare sector average of 24.9x and peer group averages of 27.0x, suggesting potential undervaluation.
Management has recently lifted its 2026 earnings outlook, indicating confidence in future profit growth despite current market pricing.
A fair value framework analysis weighing growth, profitability, size, and risk factors points to a higher P/E than where the stock currently trades.
Company updateEarnings reportGuidance raisedAI-generated analysis
Cigna Group (CI) reported a strong third quarter with net income of $1.4 billion on revenue of $73.7 billion, beating analyst expectations. While year-over-year net income declined to $1.9 billion from the prior year, adjusted earnings per share and adjusted operating income both increased, reflecting improved operational efficiencies and higher investment income. The company's stock rose 3% following the announcement.
Cigna Healthcare, covering 18.5 million people, drove significant upside with an adjusted operating income of $1.2 billion, up 15% year over year. This growth was achieved despite elevated medical costs, which were more than offset by premium hikes secured earlier in the year. The division maintained a medical loss ratio of 85%, slightly better than analyst expectations.
The company significantly boosted its 2026 financial outlook for the third time this year, raising adjusted income from operations guidance to at least $30.60 per share. CEO Brian Evanko highlighted strong performance in specialty pharmacy and expressed confidence in profitable growth for 2027, citing improving stop-loss margins and productivity initiatives. However, the PBM segment faced headwinds due to a transition to a new transparency model called Signature.
Cigna's Specialty segment saw earnings rise 15% year over year, driven by the adoption of cheaper biosimilars and generics, with Revlimid penetration reaching approximately 90%. Conversely, Express Scripts reported adjusted operating income down 22% as it incurs heavy costs to transition its pharmacy benefits model. The company also faces regulatory scrutiny regarding PBM consolidation and upcoming changes in GLP-1 coverage.
📈 Cigna raised 2026 adjusted income outlook to at least $30.60 per share.
💰 Net income hit $1.4 billion on $73.7 billion revenue, beating expectations.
🏥 Cigna Healthcare operating income rose 15% despite elevated medical costs.
⚖️ Regulatory headwinds include new DOL rules and potential PBM breakup proposals.
📉 ACA exchange exit will remove contribution from that specific business line.
📈 Cigna boosted its 2026 outlook for adjusted income from operations to at least $30.60 per share, marking the third annual increase.
💰 The company reported net income of $1.4 billion on revenue of $73.7 billion in the quarter, exceeding analyst expectations.
📊 Cigna Healthcare drove bulk upside with adjusted operating income up 15% year over year to $1.2 billion despite elevated medical costs.
💊 Specialty pharmacy earnings surged 15% year over year as adoption of cheaper biosimilars and generics accelerated.
🔄 Express Scripts adjusted operating income fell 22% year over year due to heavy spending on transitioning to the new Signature model.
📉 The medical loss ratio for Cigna Healthcare was 85%, slightly higher than last year but better than analyst expectations.
🚀 CEO Brian Evanko stated the company is well-positioned for profitable growth in 2027 with improving stop-loss margins.
⚖️ Cigna faces regulatory headwinds as it navigates new Department of Labor transparency rules and potential PBM breakup proposals.
📉 Express Scripts will face financial pressure from the industry-wide shift away from rebates and shrinking employer GLP-1 coverage.
🏥 Cigna is set to exit the Affordable Care Act exchanges, which will remove contribution from that specific business line.
Bullish Signals
Cigna raised 2026 adjusted income outlook to $30.60 per share.
Risk Factors
Express Scripts operating income declined 22% YoY during transition.
Bullish Signals
Cigna boosted its 2026 outlook for adjusted income from operations to at least $30.60 per share, up from the previous guidance of $30.45.
The company reported net income of $1.4 billion on revenue of $73.7 billion in the quarter, beating analyst expectations.
Cigna Healthcare adjusted operating income increased 15% year over year to $1.2 billion driven by improved operational efficiencies and higher investment income.
Specialty pharmacy earnings rose 15% year over year despite only a 1% revenue increase, fueled by stronger adoption of cheaper biosimilar and specialty generic drugs.
Cigna's stock price rose 3% following the release of third-quarter results that exceeded Wall Street expectations.
CEO Brian Evanko highlighted that deliberate portfolio shaping over several years is delivering tangible financial results.
Risk Factors
Express Scripts adjusted operating income declined 22% year over year as the company spends heavily to transition to a new pharmacy benefits model called Signature.
The medical loss ratio for Cigna Healthcare was 85%, which is slightly higher than the 84.8% recorded in the same quarter last year.
Express Scripts faces financial pressure related to the industrywide shift away from rebates and shrinking employer coverage of GLP-1s for weight loss.
Cigna's specialty division faces a more limited pipeline for biosimilar and specialty generic launches according to executives.
The company is set to exit the Affordable Care Act exchanges, which will remove the contribution from that business line.
Growing regulatory scrutiny on PBMs includes efforts at state and federal levels to reform the industry, with some calling for vertically consolidated behemoths to be broken up.
Cigna Group is preparing to release its third-quarter earnings report before the U.S. market opens on Thursday, November 5, 2026. Investors are closely monitoring the results as analysts have adjusted their revenue growth expectations downward compared to the previous year's performance.
Analysts currently project Cigna's revenue to grow by approximately 4.5% year over year for the September quarter, a significant deceleration from the 9.2% increase recorded in the same period last year. This shift reflects broader market trends where major competitors like Elevance Health and UnitedHealth recently reported flat revenue growth despite beating earnings estimates.
Market participants are focusing on key operational metrics including medical-cost trends, customer retention rates, and execution capabilities as central factors for the upcoming assessment. Cigna recently added 55,000 customers in the prior quarter to reach a total of 16.68 million, providing a baseline for evaluating future expansion pace.
Prior to the earnings release, Cigna shares have outperformed the broader health insurance sector, gaining 8.5% over the past month compared to an average gain of 2.8% for peers. The stock is currently trading at 267.75 euros, with analysts maintaining an average price target of 342.29 U.S. dollars ahead of the results.
📅 Cigna releases Q3 results before U.S. market opens Thursday, Nov 5.
📉 Revenue growth expected to slow to 4.5% year over year in Q3.
🏥 Investors focus on medical-cost trends and contract profitability for earnings.
👥 Customer base reached 16.68 million after adding 55,000 last quarter.
📈 Shares gained 8.5% this month, outperforming health insurance peers.
📅 Cigna Group is scheduled to publish its third-quarter financial results before the U.S. market opens on Thursday, November 5, 2026.
📉 Analysts expect Cigna's revenue growth to slow to 4.5% year over year in Q3, down from 9.2% in the same quarter last year.
🏥 Investors are prioritizing medical-cost trends and contract profitability as critical issues for the upcoming earnings assessment.
👥 The company added 55,000 customers in the previous quarter, bringing its total customer base to 16.68 million.
📈 Cigna shares have gained 8.5% over the past month, significantly outperforming the average 2.8% gain for health insurance provider peers.
💰 The average analyst price target for Cigna Group stands at 342.29 U.S. dollars as of Wednesday, November 4.
🗣️ Management is set to host a conference call at 8:30 a.m. Eastern Time following the release of financial data by 6:30 a.m.
Bullish Signals
Shares gained 8.5% vs 2.8% peer average last month.
Added 55,000 customers, reaching 16.68 million total.
Risk Factors
Revenue growth expectations lowered to 4.5% vs 9.2% prior year.
Competitor flat revenue raises medical cost and contract profit concerns.
Bullish Signals
Cigna Group shares have outperformed the broader health insurance sector, gaining 8.5% over the past month compared to an average peer gain of 2.8%.
The company successfully added 55,000 customers in the previous quarter, expanding its total customer base to 16.68 million.
Risk Factors
Analysts have lowered their revenue growth expectations for Q3 to 4.5% year over year, a significant slowdown from the 9.2% increase recorded in the same quarter last year.
Recent performance from major competitors like Elevance Health and UnitedHealth, which reported flat revenue, highlights concerns regarding medical-cost trends and contract profitability for Cigna.
Wall Street analysts project Cigna (CI) to report quarterly earnings of $7.46 per share, representing a year-over-year decline of 4.7%. Revenue is expected to reach $73.53 billion, marking a 5.7% increase from the prior-year quarter. Over the last 30 days, there have been no revisions to the consensus EPS estimate, indicating stability in analyst expectations despite the projected earnings drop.
Analysts forecast specific segment revenues, with Evernorth Health Services expected to generate $64.06 billion (+6.1% YoY) and Cigna Healthcare generating $11.65 billion (+6.6% YoY). Within the U.S. Commercial segment, stop-loss premiums are projected at $2.18 billion (+14.1% YoY), while employer-insured premiums are estimated at $4.99 billion (+6.1% YoY). The Medical Care Ratio is anticipated to remain steady at 85.1%, slightly up from the year-ago value of 84.8%.
Customer metrics show growth in total medical customers, which analysts estimate will reach 18.37 million compared to 18.06 million last year. Administrative services only customers are projected at 14.20 million for U.S. Healthcare, up from 13.79 million previously. However, pharmacy claim volume is expected to decrease slightly to 553.94 million from 558.00 million a year ago. International health covered lives are forecasted at 1.62 million, down from 1.71 million in the same quarter last year.
Cigna shares have outperformed the broader market recently, rising 10.2% over the past month compared to the S&P 500's decline of 0.9%. Despite this recent strength, Zacks Investment Research maintains a Rank #3 (Hold) rating for CI, suggesting the stock is expected to mirror overall market performance in the near future rather than showing significant directional momentum based on current analyst consensus.
📈 Analysts project Cigna quarterly EPS of $7.46, down 4.7% year-over-year.
💰 Revenue expected to reach $73.53 billion, up 5.7% from prior quarter.
🏥 Evernorth Health Services revenues forecast at $64.06 billion, up 6.1%.
👥 Total medical customers projected at 18.37 million, surpassing last year.
Cigna Group has announced a quarterly cash dividend of USD 1.56 per common share, payable on December 17, 2026, to shareholders of record as of the close of business on December 3, 2026. The board declared this distribution on October 28, providing income-oriented investors with a defined cash-distribution timetable ahead of the company's upcoming earnings release.
The Cigna Group is scheduled to report its third-quarter 2026 results on November 5, 2026, which will provide investors with the next critical read on revenue, earnings, and broader business trends. This operating performance update follows the shareholder-return decision and serves as a key checkpoint for assessing the company's financial health after serving more than 180 million customer relationships worldwide.
Operating through subsidiaries including Cigna Healthcare and Evernorth Health Services, the company maintains sales capabilities in over 30 markets and jurisdictions globally. While the dividend announcement signals a commitment to returning capital, it does not inherently signal a change in underlying operating performance, leaving market focus on the upcoming November earnings report for fresh insights into business trends.
📅 CI declares $1.56 quarterly dividend payable Dec 17, 2026.
📊 Shareholders of record by Dec 3, 2026 qualify for payment.
📈 Q3 2026 results release scheduled for Nov 5, 2026.
🌍 CI serves 180M+ customers across 30 global markets.
💼 Segments include Cigna Healthcare and Evernorth Health Services.
📅 Cigna Group declared a quarterly cash dividend of USD 1.56 per common share payable on December 17, 2026.
📊 Shareholders of record at the close of business on December 3, 2026, will qualify for the upcoming dividend payment.
📈 Third-quarter 2026 results are scheduled for release on November 5, 2026, focusing on revenue and earnings performance.
🌍 The company serves more than 180 million customer relationships worldwide across over 30 markets and jurisdictions.
💼 Operating segments include Cigna Healthcare and Evernorth Health Services with global sales capabilities.
📉 The dividend announcement provides a cash distribution timetable but does not signal an immediate change in operating performance.
Bullish Signals
Declared quarterly dividend of USD 1.56 per share.
Serves over 180 million customers globally via subsidiaries.
Risk Factors
Dividend cut signals no immediate operational improvement.
Investors await Nov 5 earnings for business trends.
No change in underlying operating performance noted.
Bullish Signals
Cigna Group declared a quarterly cash dividend of USD 1.56 per common share, demonstrating a commitment to returning capital to shareholders and providing income-oriented investors with a defined cash-distribution timetable.
The company maintains a robust global footprint serving more than 180 million customer relationships worldwide through its diverse subsidiaries including Cigna Healthcare and Evernorth Health Services.
Risk Factors
The dividend announcement is explicitly noted as not signaling an immediate change in underlying operating performance, meaning investors must rely on the upcoming November 5 earnings report for fresh insights into business trends.
Company updateEarnings reportAI-generated analysis
Cigna Group (NYSE: CI) reported Q2 2026 results with adjusted EPS of $7.78, marking an 8% increase year-over-year despite a 27% decline in Pharmacy Benefit Services profit. The company is now preparing to report Q3 2026 earnings on November 5, 2026, which will be critical for determining if the pharmacy benefit profit decline has bottomed out as specialty growth momentum slows.
Management reaffirmed its full-year adjusted EPS guidance of at least $30.45 and total revenue of approximately $280 billion during a September investor day. The company's business mix continues to shift, with Cigna Healthcare showing strong 17% profit growth while the pharmacy segment faces headwinds from client renewal concessions and spending on its rebate-free Signature model.
Three key metrics will define Q3 performance: whether Pharmacy Benefit Services profit stabilizes after significant declines, if Specialty and Care Services can sustain rapid growth following biosimilar switching peaks, and if Cigna Healthcare's Medical Care Ratio remains stable. The company has raised its full-year EPS outlook to at least $30.45, implying a minimum of $14.87 in the second half.
Cigna is executing a strategic transformation involving the sale of its Medicare Advantage business for $4.9 billion and an upcoming exit from Individual and Family Plans in 2027. Leadership changes include Brian Evanko succeeding David Cordani as CEO, alongside a new 'Lead to One' direction focused on modernization initiatives totaling $3 billion over multiple years.
📈 Cigna Q2 adjusted EPS rose 8% to $7.78 with revenue up 7% to $71.668 billion.
🚀 Cigna Healthcare profit surged 17% to $1.276 billion driven by strong employer business performance.
💰 Management reaffirmed full-year adjusted EPS guidance of at least $30.45 and revenue near $280 billion.
🔄 Company sold Medicare Advantage business for $4.9 billion in March 2025 to Health Care Service Corporation.
👔 Brian Evanko succeeded David Cordani as CEO on July 1, 2026 with Cordani moving to executive chair.
📈 Cigna reported Q2 2026 adjusted EPS of $7.78 (+8%) with total revenue rising 7% to $71.668 billion.
📉 Pharmacy Benefit Services profit fell 27% in Q2 due to client renewal concessions and transition spending on the Signature model.
🚀 Cigna Healthcare profit surged 17% to $1.276 billion, driven by strong employer business performance.
💰 Management reaffirmed full-year adjusted EPS guidance of at least $30.45 and revenue of about $280 billion.
🔄 The company sold its Medicare Advantage business for $4.9 billion in March 2025 to Health Care Service Corporation.
👔 Brian Evanko succeeded David Cordani as CEO on July 1, 2026, with Cordani moving to executive chair.
🏥 Cigna Healthcare's Medical Care Ratio was 84.5% in Q2, up from 79.8% in Q1 due to seasonal factors.
💊 Specialty and Care Services profit grew 21% in the first half, offsetting declines in pharmacy benefits.
📅 Cigna is scheduled to report Q3 2026 earnings on November 5, 2026, with consensus EPS of $7.545.
🛡️ The company introduced a 'Lead to One' strategy and plans $3 billion in modernization initiatives at its investor day.
📉 Q1 and Q2 Pharmacy Benefit Services profits declined 28% and 27% respectively due to regulatory pressure and client concessions.
🏥 Cigna Healthcare serves 3.701 million fully insured members and 14.712 million ASO members as of June 30, 2026.
💸 First-half operating cash flow was $710 million, with full-year targets dependent on second-half collections.
📉 The company repurchased 11.9 million shares for about $3.6 billion in 2025 and maintains a debt-to-capitalization ratio of 42.8%.
Bullish Signals
Cigna Healthcare profit grew 17% to $1.276B in Q2.
Risk Factors
P&L profit declined 27% due to concessions and Signature model spending.
Bullish Signals
Cigna Healthcare profit grew 17% to $1.276 billion in Q2, demonstrating strong performance in the self-funded employer segment.
Specialty and Care Services profit increased 21% in the first half of 2026, successfully offsetting declines in pharmacy benefits.
Management raised full-year adjusted EPS guidance to at least $30.45 and reaffirmed revenue guidance of about $280 billion.
Cigna Healthcare's Medical Care Ratio improved to 84.5% in Q2, indicating better cost management compared to the prior quarter.
The company successfully sold its Medicare Advantage business for $4.9 billion, reducing exposure to government program risk.
Risk Factors
Pharmacy Benefit Services profit declined 27% in Q2 due to client renewal concessions and spending on the rebate-free Signature model.
Claim volume in the pharmacy segment fell 2% sequentially in Q2, adding pressure to profitability margins.
The company faces regulatory headwinds from new legislation requiring 100% rebate pass-throughs starting in August 2028.
First-half operating cash flow was only $710 million, significantly impacted by timing of accounts receivable factoring settlements.
The Cigna Group (CI) has been downgraded from a Buy to a Hold rating with a new target price of $318, which reflects a limited 4.1% upside potential. This shift in analyst sentiment comes despite the company's manageable debt levels and steady dividend payments, as management faces significant headwinds that are altering its profit trajectory.
Financial performance is being weighed down by margin pressure within its Pharmacy Benefit Manager (PBM) segment, which is offsetting growth from specialty drugs. Additionally, the strategic transition to the Signature model is introducing added costs and competitive pricing pressures, while employers increasingly push for lower fees, thereby constraining future margin expansion opportunities.
While management expects customer retention to remain stable following the implementation of the Signature model, the company has slowed its share buyback program. Analysts now believe that a clearer path to profitability is required before reinstating a Buy recommendation, highlighting concerns over the sustainability of current growth strategies amidst rising operational costs and fee compression.
📉 Downgraded to Hold with $318 target price.
💊 PBM segment faces significant margin pressure.
🔄 Signature model transition adds costs and headwinds.
The Cigna Group (CI) presents a value opportunity with a forward P/E ratio of 8.26 and an implied earnings yield of approximately 12.1%, significantly higher than the 10-year U.S. Treasury yield. The company combines its healthcare insurance business with Evernorth Health Services, diversifying revenue streams across pharmacy benefit management and specialty operations. Management raised its 2026 adjusted EPS outlook to at least $30.45, reflecting confidence in continued growth despite a low multiple that suggests the market remains cautious about earnings sustainability.
In the second quarter of 2026, CI reported revenue growth of 7% year-over-year to $71.7 billion, with adjusted EPS climbing to $7.78 and net income reaching $1.66 billion. However, financial performance faces headwinds from rising medical costs, evidenced by a medical care ratio increase to 84.5%, and regulatory pressures on pharmacy benefit margins that could squeeze profitability in the Evernorth segment. The company's net profit margin of roughly 2.3% leaves limited room for significant shocks.
CI offers an annualized dividend of $6.24 per share, yielding 2.20% with a payout ratio of 25.38%, providing a modest cushion if earnings face headwinds. While the valuation has narrowed from a forward P/E of 11.26 in mid-2025 to current levels, trading at a discount compared to peers like CVS Health, investors must weigh this against potential risks from regulatory changes and cost inflation. The stock is positioned for both income and growth, contingent on the company's ability to stabilize medical costs and maintain margins amidst industry shifts.
📈 CI Q2 2026 revenue rose 7% to $71.7 billion.
💰 Adjusted EPS reached $7.78; full-year outlook floor raised to $30.45.
📉 Forward P/E narrowed to 8.26 with a 12.1% earnings yield.
⚠️ Medical care ratio increased to 84.5% due to rising costs.
💵 CI offers a 2.20% dividend yield on a conservative 25.38% payout.
📈 CI reported Q2 2026 revenue of $71.7 billion, a 7% increase from the prior year, driven by its diversified business model combining healthcare insurance and pharmacy benefit management.
💰 Adjusted earnings per share rose to $7.78 in Q2 2026, prompting management to raise the full-year 2026 adjusted EPS outlook to a floor of $30.45.
📉 The company trades at a forward P/E of 8.26 with an implied earnings yield of 12.1%, offering a spread of roughly 6.9 percentage points over the 10-year U.S. Treasury yield.
⚠️ Medical costs are rising, pushing the medical care ratio to 84.5% from 83.2% a year earlier, which increases the portion of premiums consumed by claims.
🏛️ Evernorth Health Services faces regulatory scrutiny and potential margin compression as the industry adapts to changes in rebate structures and drug pricing mechanisms.
💵 CI pays an annualized dividend of $6.24 per share with a 2.20% yield and a conservative payout ratio of 25.38%, allowing room for future increases.
📊 The forward P/E multiple has narrowed from 11.26 in June 2025 to 8.26 currently, suggesting the market expects earnings growth but remains cautious about sustainability.
🔍 CI's net profit margin stands at approximately 2.3%, indicating that even small adverse shocks could significantly impact overall profitability.
🆚 The stock trades at a relative discount compared to CVS Health (CVS), which has a forward P/E of 10.67, though business mix differences complicate direct comparisons.
Bullish Signals
Revenue grew 7% YoY to $71.7B in Q2 2026.
Management raised full-year 2026 EPS outlook to $30.45.
Stock trades at forward P/E of 8.26 with 12.1% yield.
Offers $6.24 annualized dividend with 25.38% payout ratio.
Diversified model reduces reliance on single segment.
Risk Factors
Medical care ratio rose to 84.5% from 83.2%.
Evernorth faces regulatory pressure on pharmacy benefits.
Net profit margin is only 2.3%.
Bullish Signals
Cigna Group reported strong Q2 2026 revenue growth of 7% year-over-year, reaching $71.7 billion, demonstrating resilience in its core healthcare and pharmacy benefit businesses.
Management raised the full-year 2026 adjusted EPS outlook to at least $30.45, signaling confidence in future earnings performance despite market headwinds.
The stock trades at an attractive forward P/E of 8.26 with an implied earnings yield of 12.1%, offering a significant spread over the 10-year U.S. Treasury yield.
CI offers a sustainable annualized dividend of $6.24 per share with a low payout ratio of 25.38%, providing income stability and potential for future increases.
The company's diversified business model, combining Cigna Healthcare and Evernorth Health Services, generates earnings from multiple sources, reducing reliance on any single segment.
Risk Factors
Rising medical costs have increased the medical care ratio to 84.5% from 83.2% a year earlier, indicating that claims are consuming a larger portion of premiums.
Evernorth Health Services faces regulatory pressure on pharmacy benefit management and potential margin squeezing as industry dynamics regarding rebates and drug pricing evolve.
The company's net profit margin is only about 2.3%, leaving little room for large shocks or errors in cost estimation to impact the bottom line significantly.
Cigna Group (CI) shares fell 2.91% to close near $306.70, failing to sustain momentum above the $315.72 intraday high and trading near its 52-week peak of $316.27. The decline was driven primarily by technical overextension rather than fundamental deterioration, as the stock's Relative Strength Index (RSI) spiked to an extreme 88.4, signaling an overbought condition that prompted profit-taking among algorithmic and institutional traders.
Despite the short-term pullback, analysts maintain a 'Moderate Buy' rating with a price target of $338.24, implying approximately 10.1% upside from current levels. The stock trades at a dynamic P/E ratio of roughly 12.23 and offers a healthy dividend yield of 2.05%, suggesting the long-term bullish trend remains intact despite the technical reset.
The selling pressure on Cigna was not isolated but mirrored broader weakness in the Managed Health Care sector, with competitor UnitedHealth Group (UNH) also dropping 1.69%. This correlation indicates that the move is partly driven by sector-wide rotation or macroeconomic concerns affecting large-cap healthcare insurers rather than company-specific news.
Technically, Cigna is trading well above its key moving averages, including the 200-day average at $280.94 and the 100-day average at $283.43, which serve as strong support levels. The stock recently pierced its upper Bollinger Band, a common trigger for mean reversion, making a pullback toward the $285-$290 range technically probable to cool the RSI before potentially resuming its upward trajectory.
📉 CI shares dropped 2.91% to $306.70 amid sector weakness.
📊 Extreme RSI of 88.4 signals overbought conditions and profit-taking.
🎯 Analysts rate CI 'Moderate Buy' with $338.24 price target.
💰 CI trades at P/E of 12.23 with 2.05% dividend yield.
Cigna Group stock closed at EUR 268.25 on the Xetra exchange on October 16, 2026. The company recently introduced a new initiative called Health Sense, which is designed to connect health, care, benefits, costs, and prior interactions for its customers.
Launched on October 6, 2026, the Health Sense platform represents a personalized customer and clinical support model. According to the company's release, this new model is projected to reduce inefficient healthcare spending by 10 percent by the year 2030.
The rollout of the Health Sense platform is scheduled to begin in early 2027. Initially, the program will focus on customers with specific oncology and cardiometabolic health needs before expanding further.
📈 Cigna Group stock closed at EUR 268.25 on Xetra on October 16, 2026.
🚀 Company launched Health Sense personalized support model on October 6, 2026.
💰 Platform projected to cut inefficient healthcare spending by 10 percent by 2030.
📅 Rollout begins early 2027 focusing on oncology and cardiometabolic health needs.
📈 Cigna Group stock closed at EUR 268.25 on the Xetra exchange on October 16, 2026.
🚀 The company introduced Health Sense on October 6, 2026, a new personalized customer and clinical support model.
💰 The Health Sense platform is projected to reduce inefficient healthcare spending by 10 percent by 2030.
📅 The rollout of the Health Sense initiative is scheduled to begin in early 2027.
🎯 Initial deployment will focus on customers with oncology and cardiometabolic health needs.
Bullish Signals
Launched Health Sense for personalized patient support.
Platform aims to cut healthcare spending 10% by 2030.
Bullish Signals
Cigna Group introduced Health Sense, a new personalized customer and clinical support model designed to connect health, care, benefits, costs, and prior interactions.
The company projects that the Health Sense platform will reduce inefficient healthcare spending by 10 percent by 2030.
Cigna Group stock traded at EUR 268.45 on October 16, 2026, remaining unchanged from the previous Xetra close and sitting just 0.65 percent below its 52-week high of EUR 270.20. The company reaffirmed its adjusted earnings per share guidance for 2026 at a minimum of USD 30.45, a benchmark established in a September 30 release distributed by PR Newswire.
As of the reporting date, Cigna Group held a market capitalization of USD 79.7 billion with a price-to-earnings ratio of 12.49. The stock's 52-week trading range spanned from EUR 208.40 to EUR 270.20, placing the current quote 28.82 percent above the yearly low. Investors are awaiting the scheduled release of third-quarter 2026 results on November 5, 2026, which will provide a concrete test of the company's maintained earnings guidance.
The primary listing for Cigna shares is on the NYSE, where the stock closed at USD 301.51 on October 16, 2026. The healthcare giant operates within the Medical - Healthcare Plans sector and continues to be a key player in the broader health insurance landscape alongside peers like UnitedHealth Group and CVS Health.
📈 CI stock traded flat at EUR 268.45 on October 16, 2026.
🎯 CI reaffirmed adjusted EPS guidance of at least USD 30.45 for FY2026.
💰 CI market cap reached USD 79.7 billion with a P/E of 12.49.
📅 CI will release Q3 2026 results on November 5, 2026.
📉 CI shares sit 0.65% below the 52-week high of EUR 270.20.
📈 Cigna Group stock traded at EUR 268.45 on October 16, 2026, remaining flat versus the prior Xetra close.
🎯 The company reaffirmed adjusted earnings per share guidance of at least USD 30.45 for the fiscal year 2026.
💰 Cigna Group reported a market capitalization of USD 79.7 billion and a price-to-earnings ratio of 12.49 as of October 16, 2026.
📅 Third-quarter 2026 results are scheduled for release on November 5, 2026, to validate the maintained earnings guidance.
📉 The stock price sits 0.65 percent below its 52-week high of EUR 270.20 and 28.82 percent above its yearly low.
🏢 Cigna Group is listed on the NYSE with a primary share price of USD 301.51 as of October 16, 2026.
Bullish Signals
Cigna reaffirmed 2026 EPS guidance at minimum USD 30.45.
Stock trades near 52-week high showing strong sentiment.
Cigna Group reaffirmed its adjusted earnings per share guidance for 2026 at a minimum of USD 30.45, demonstrating management confidence in meeting financial targets.
The stock is trading near its 52-week high, indicating strong market sentiment and investor interest in the company's current valuation.
Risk Factors
Cigna Group stock is currently trading just 0.65 percent below its 52-week high, suggesting limited immediate upside momentum from current levels.
Cigna Group has launched Health Sense, a personalized care model designed to reduce inefficient healthcare spending by 10% by 2030. The initiative, which targets oncology and cardiometabolic conditions, is scheduled to begin operations in early 2027. This strategic launch follows strong financial performance in the second quarter of 2026, providing a solid revenue base for the new program.
Second-quarter 2026 results showed total revenue reaching USD 71.7 billion, representing a 7% increase year-over-year. Adjusted earnings per share climbed to USD 7.78, driven by significant growth in Specialty and Care Services, which saw pre-tax adjusted earnings rise 22% to USD 1.1 billion. Cigna Healthcare revenue specifically grew 10% to USD 11.8 billion.
Management has raised its full-year 2026 adjusted earnings per share guidance to at least USD 30.45 and reaffirmed a long-term target of 10% to 14% annual growth through 2030. The company is set to release third-quarter results on November 5, 2026, with the Health Sense launch marking a concrete operational benchmark for its future strategy.
Analyst Piper Sandler has maintained a target price of USD 370 for Cigna Group stock. The market capitalization stands at approximately USD 67.9 billion as of mid-October 2026. Investors are closely watching the execution of Health Sense to validate the company's broader model and margin expansion capabilities.
🚀 Cigna launches Health Sense targeting 10% spending reduction by 2030.
💰 Q2 2026 revenue hit USD 71.7 billion, up 7% year-over-year.
Cigna Group reported second-quarter 2026 revenue of USD 71.70 billion, surpassing the consensus estimate of USD 70.18 billion. The company's adjusted earnings per share reached USD 7.78, exceeding the forecast of USD 7.59. This strong financial performance has reinforced UBS's Buy rating and maintained its price target at USD 400.00 for Cigna Group stock.
Cigna reaffirmed its full-year 2026 outlook with adjusted revenue guidance of approximately USD 280 billion and adjusted earnings per share of at least USD 30.45. The company also highlighted a significant USD 3.00 billion modernization and productivity initiative planned through 2030 to drive future efficiency and growth.
Valuation metrics show Cigna trading with a P/E ratio of 11.69, which is notably lower than peers UnitedHealth Group (P/E 21.56) and Elevance Health (P/E 18.90). The stock's market capitalization stands at USD 74.7 billion, reflecting investor interest in its undervalued multiple relative to the broader healthcare sector.
The article notes that Cigna's current trading price in euros sits below its primary-exchange quote range, while maintaining a dividend yield of 2.00 percent. Analysts view the company's lower valuation as a potential opportunity given its solid revenue beat and clear strategic roadmap for productivity improvements.
📈 CI beat Q2 2026 revenue estimates with USD 71.70 billion.
Company updateEarnings reportAI-generated analysis
The Cigna Group (CI), headquartered in Bloomfield, Connecticut, is a global health company serving over 185 million customer relationships across more than 30 markets. With a market capitalization of $74.6 billion, the company is preparing to report its Q3 earnings on Thursday, November 5, 2026, before the market opens.
Ahead of the earnings release, analysts project diluted EPS of $7.46 for the quarter, representing a 4.7% decline from the year-ago figure of $7.83. Despite this expected dip, CI has exceeded Wall Street's EPS estimates in each of the past four quarters, highlighting a consistent track record of earnings outperformance.
Looking further ahead, fiscal 2026 analysts expect CI to report EPS of $30.50, up 2.2% from fiscal 2025, with projections reaching $33.46 for fiscal 2027. Over the past two years, revenue has grown at an annual rate of 13.8%, while EPS has increased by 12% annually over the last five years.
CI stock has underperformed the broader market and healthcare sector over the past 52 weeks, declining 5.8% compared to gains for the S&P 500 and the State Street Health Care Select Sector SPDR ETF. However, the company recently introduced 'Health Sense,' a personalized support model aimed at reducing inefficient healthcare spending by 10% by 2030, which caused shares to rise 1.1% following the announcement.
📅 CI reports Q3 earnings Nov 5, 2026, with expected EPS of $7.46.
📈 CI beat EPS estimates for four consecutive quarters despite lower guidance.
📉 Stock declined 5.8% over 52 weeks while customer base shrank 8.1%.
💵 Revenue grew 13.8% annually, with analysts projecting fiscal 2026 EPS of $30.50.
🏥 New Health Sense model aims to cut healthcare spending by 10% by 2030.
📅 CI is scheduled to report Q3 earnings on Thursday, November 5, 2026, before the market opens.
💰 Analysts expect diluted EPS of $7.46 for Q3 2026, down 4.7% from $7.83 in the year-ago quarter.
📈 CI has exceeded Wall Street's EPS estimates in each of the past four quarters despite current expectations.
🔮 For fiscal 2026, analysts project EPS of $30.50, up 2.2% from fiscal 2025, with further growth to $33.46 in fiscal 2027.
📉 CI stock has declined 5.8% over the past 52 weeks, underperforming the S&P 500 and the Health Care Select Sector SPDR ETF.
👥 The company faces concerns about customer retention, with its customer base declining by an average of 8.1% over the past two years.
💵 Revenue has grown at an annual rate of 13.8% over the past two years, while EPS increased by 12% annually over the last five years.
🏥 CI introduced 'Health Sense,' a personalized support model targeting oncology and cardiometabolic conditions to reduce inefficient healthcare spending by 10% by 2030.
📈 Following the Health Sense announcement, CI shares rose 1.1% in the market.
👍 Analysts maintain a consensus 'Moderate Buy' rating on CI stock with an average price target of $342.26.
Bullish Signals
Exceeded EPS estimates for four consecutive quarters.
Revenue grew 13.8% annually over past two years.
EPS increased 12% annually over last five years.
Health Sense projected to cut spending by 10%.
Shares rose 1.1% on Health Sense launch.
Risk Factors
Q3 2026 EPS expected to decline 4.7% to $7.46.
Stock down 5.8% in 52 weeks, underperforming peers.
Customer base declined 8.1% average over two years.
Bullish Signals
The Cigna Group has exceeded Wall Street's EPS estimates in each of the past four quarters, demonstrating a consistent track record of earnings outperformance.
Revenue has grown at an annual rate of 13.8% over the past two years, indicating strong underlying business growth despite customer retention challenges.
EPS has increased by 12% annually over the last five years, reflecting sustained profitability and operational efficiency.
The launch of 'Health Sense' is projected to reduce inefficient healthcare spending by 10% by 2030, potentially improving margins and patient outcomes.
Following the announcement of Health Sense, CI shares rose 1.1%, indicating positive market reaction to the new initiative.
Analysts maintain a consensus 'Moderate Buy' rating on CI stock, with 14 out of 23 analysts recommending a 'Strong Buy'.
Risk Factors
Analysts expect diluted EPS of $7.46 for Q3 2026, representing a 4.7% decline from the year-ago figure of $7.83.
CI stock has declined 5.8% over the past 52 weeks, significantly underperforming both the S&P 500 and the Health Care Select Sector SPDR ETF.
The company faces concerns about customer retention, with its customer base declining by an average of 8.1% over the past two years.
Company updateFinancial outlookAI-generated analysis
Cigna Group stock is trading at EUR 241.80 in pre-market sessions, representing a gain of 1.13% against the prior close of EUR 239.10 recorded on October 2, 2026. The current market activity shows a bid of EUR 239.90 and an ask of EUR 243.70, with real-time quotes expected to update following the Xetra open at 9:00 a.m. CEST.
In a release dated September 30, 2026, The Cigna Group unveiled its 'Lead to One' vision and announced a significant $3 billion multi-year initiative focused on modernization and productivity improvements. This strategic move is designed to streamline operations and enhance efficiency across the organization's extensive healthcare network.
The company has reaffirmed its full-year 2026 guidance, projecting adjusted revenue of approximately $280 billion and adjusted earnings per share of at least $30.45. Furthermore, Cigna Group provided a long-term target for compound annual growth in adjusted earnings per share ranging from 10% to 14% through the year 2030.
Looking ahead to the period between 2026 and 2030, the insurer expects to generate approximately $50 billion in cumulative operating cash flow. These financial targets underscore the company's confidence in its strategic transformation and ability to deliver sustained value to shareholders over the next several years.
📈 CI stock trades up 1.13% at EUR 241.80 pre-market.
💰 CI reaffirmed 2026 adjusted EPS guidance of at least $30.45.
🚀 CI launches $3 billion 'Lead to One' modernization initiative.
📅 CI targets 10-14% annual EPS growth through 2030.
💵 CI expects $50 billion cumulative operating cash flow by 2030.
📈 Cigna Group stock is trading at EUR 241.80 pre-market, up 1.13% from the prior close of EUR 239.10.
💰 The company reaffirmed 2026 guidance for adjusted revenue of about $280 billion and adjusted EPS of at least $30.45.
🚀 Cigna Group announced a $3 billion multi-year modernization and productivity initiative under its 'Lead to One' vision.
📅 The insurer targets 10% to 14% compound annual growth in adjusted earnings per share through 2030.
💵 Management expects approximately $50 billion in cumulative operating cash flow for the 2026-2030 period.
🏢 Current market data shows a bid of EUR 239.90 and an ask of EUR 243.70 ahead of the Xetra open.
Bullish Signals
Revenue projected at $280B for 2026.
EPS growth target of 10-14% CAGR to 2030.
Announced $3B investment in modernization initiative.
Cigna Group reported adjusted Q2 2026 earnings per share of USD 7.78, surpassing the consensus estimate of USD 7.60. However, quarterly revenue of USD 70.04 billion fell slightly short of the USD 70.14 billion market expectation. The stock held steady at USD 272.01 on the NYSE ahead of a significant investor day scheduled for September 30, 2026.
Analyst coverage from Evercore ISI initiated with an In Line rating and a price target of USD 290.00, citing execution risk as Cigna transitions its pharmacy benefit management business toward a rebate-free model. The firm projects adjusted operating income growth of 2.00 percent annually for the pharmacy services business through 2030.
The upcoming investor day is critical for clarifying how much future growth depends on execution rather than volume alone, specifically regarding the economics of the pharmacy benefit management operation which remains a major earnings driver. The company aims to reach an operating margin of 1.60 percent in 2028 compared to 2.70 percent in 2025.
Cigna Group has a market capitalization of USD 71.9 billion and a 52-week trading range between USD 239.51 and USD 315.47. Investors are closely watching the September 30 presentation to determine if Cigna can protect profitability while successfully changing the economics of its pharmacy benefit management business.
📈 CI beat Q2 EPS estimates at USD 7.78 despite missing revenue expectations.
⚠️ Analysts warn of execution risk during PBM rebate-free model transition.
The Cigna Group reported second-quarter 2026 results that exceeded analyst expectations on both revenue and earnings per share. Total revenue reached $71.56 billion, representing a 6.6% year-over-year increase to $71.56 billion from the prior year's $67.10 billion. Earnings per share rose to $7.78, surpassing the consensus estimate of $7.58 by $0.20 and growing from $7.20 in the same period last year.
Segment performance highlighted a divergence between the company's pharmacy benefit management unit and its healthcare insurance business. Evernorth Health Services generated $61.47 billion in revenue, up 6.3% year over year, while Cigna Healthcare posted stronger growth with revenue reaching $11.84 billion, an increase of 9.6%. Both segments reported results above their respective consensus estimates.
Despite the solid earnings beat, Cigna's stock price fell 1.03% to close at $265.50 on September 24, 2026. The share price remains significantly below its 52-week high of $315.47, trading at a market capitalization of approximately $70.16 billion. Analysts note that while the earnings execution was strong, the stock's reaction reflects ongoing concerns regarding the transition within the pharmacy benefit management business.
Market sentiment remains mixed as investors await further clarity on how the PBM transition will impact future profit growth. Upcoming investor events scheduled for September 30, 2026, are expected to provide additional details on management's strategy for navigating this shift. Analyst ratings vary, with some firms maintaining buy ratings while others cite transition risks as a primary concern for the stock's near-term trajectory.
📈 Cigna Q2 revenue rose 6.6% to $71.56 billion.
💰 EPS beat estimates at $7.78, driven by Healthcare growth.
Cigna Group (CI) shares closed at $274.47 on the NYSE on September 21, 2026, marking a 0.3 percent decline from the prior session. The stock underperformed the broader market as the S&P 500 gained 1.5 percent during the same trading period.
As of September 21, 2026, Cigna Group held a market capitalization of $72.526 billion. The company is scheduled to host an Investor Day event on September 30, 2026, and has a dividend payable date set for September 23, 2026.
📉 CI stock closed down 0.3% at $274.47.
📊 CI shares underperformed the S&P 500's 1.5% gain.
💰 CI market cap stands at $72.526 billion.
📅 CI Investor Day is scheduled for Sept 30, 2026.
💸 CI dividend payment due on Sept 23, 2026.
📉 Cigna Group stock finished the session at $274.47, representing a 0.3 percent decline.
📊 The shares underperformed the S&P 500, which rose by 1.5 percent on September 21, 2026.
💰 Cigna Group reported a market capitalization of $72.526 billion as of the close on September 21, 2026.
📅 An Investor Day event is scheduled to take place on September 30, 2026.
💸 A dividend payment is due to shareholders on September 23, 2026.
Risk Factors
Stock declined 0.3%, underperforming S&P 500 gain of 1.5%.
Risk Factors
Cigna Group stock declined by 0.3 percent, underperforming the S&P 500 which gained 1.5 percent in the same session.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)